This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2013 Jul;117(1):285.

doi: 10.1213/ANE.0b013e3182942954.

Context sensitive decrement times of remimazolam

Thomas Schnider, Charles Minto

PMID: 23788743
DOI: 10.1213/ANE.0b013e3182942954

Comment

Context sensitive decrement times of remimazolam

Thomas Schnider et al. Anesth Analg. 2013 Jul.

. 2013 Jul;117(1):285.

doi: 10.1213/ANE.0b013e3182942954.

Authors

Thomas Schnider, Charles Minto

PMID: 23788743
DOI: 10.1213/ANE.0b013e3182942954

No abstract available

PubMed Disclaimer

Comment on

A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part II. Population pharmacokinetic and pharmacodynamic modeling and simulation.
Wiltshire HR, Kilpatrick GJ, Tilbrook GS, Borkett KM. Wiltshire HR, et al. Anesth Analg. 2012 Aug;115(2):284-96. doi: 10.1213/ANE.0b013e318241f68a. Epub 2012 Jan 16. Anesth Analg. 2012. PMID: 22253270 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wolters Kluwer
Other Literature Sources
- scite Smart Citations